» Articles » PMID: 37094596

Effect of Rituximab on Immune Status in Children with Mature B-cell Non-Hodgkin Lymphoma: a Prespecified Secondary Analysis of the Inter-B-NHL Ritux 2010 Trial

Abstract

Background: Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma is improved by the addition of rituximab to chemotherapy. The effect of rituximab on immune reconstitution after therapy has not been well described. Herein, we evaluate the immune effects of the addition of rituximab to intensive chemotherapy, a prespecified secondary aim of the Inter-B-NHL Ritux 2010 trial.

Methods: The Inter-B-NHL Ritux 2010 trial was an international, open-label, randomised, phase 3 trial in children (age 6 months to 18 years) with high-risk, mature B-cell non-Hodgkin lymphoma, comparing chemotherapy alone or chemotherapy with rituximab. Measures of immune status were completed at baseline, 1 month from the end of treatment, and 1 year from the start of therapy, and yearly thereafter until normalised. For this secondary analysis, we report on the proportions of patients with low lymphocyte counts and immunoglobulin concentrations at these timepoints with total lymphocyte count, B-cell count, and IgG concentration as the main endpoints. Other endpoints of interest included exposure to immunoglobulin replacement therapy and vaccine serologies. The population assessed for immune endpoints was the eligible per-protocol population with at least one immune parameter at one timepoint. Comparisons of immune status were made between the randomised treatment groups. Safety in the post-therapy period was assessed in the population eligible for the immunity study who were followed up at least 3 months after the end of treatment and without cancer-related events. The Inter-B-NHL Ritux 2010 study was registered with ClinicalTrials.gov, NCT01516580; status completed, with analyses of secondary aims ongoing.

Findings: From Dec 19, 2011, to June 13, 2017, 421 patients (344 [82%] boys and 77 [18%] girls; mean age was 8·8 years [SD 4·1]) were enrolled and had immune data at baseline during follow-up, or both. The study population included randomly assigned patients (n=289) and a non-randomised cohort enrolled after the planned interim analysis (n=132). At baseline, 99 (34%) of 290 patients with available data (excluding patients with bone marrow disease with peripheral blast cells) had lymphopenia, and 178 (48%) of 368 had hypogammaglobulinemia. 1 month from the end of therapy, patients who received chemotherapy with rituximab were more likely than those who received chemotherapy alone to have lymphopenia (86 [81%] of 106 vs 53 (60%) of 89, odds ratio [OR] 2·92 [95% CI 1·53-5·57], p=0·0011), B-cell lymphopenia (72 [96%] of 75 vs 36 [64%] of 56, OR 13·33 [3·71-47·84], p<0·0001), and hypogammaglobulinemia (67 [71%] of 95 vs 37 [47%] of 79, OR 2·72 [1·45-5·07], p=0·0017). Differences remained at 1 year for hypogammaglobulinemia only (52 [55%] of 94 vs 16 [25%] of 63, OR 3·64 [1·81-7·31], p=0·0003). Patients in the chemotherapy with rituximab group were more likely than those in the chemotherapy group to receive immunoglobulin replacement (26 [16%] 164 vs nine [7%] of 158, hazard ratio [HR] 2·63 [95% CI 1·23-5·62], p=0·010), mainly due to low immunoglobulin concentration. In the combined treatment groups, including non-randomly assigned patients, the proportion of patients who had loss of protective serologies to a vaccine preventable infection varied from four (9%) of 47 for polio to 21 (42%) of 50 for Streptococcus pneumoniae (pneumococcus). One patient (chemotherapy with rituximab group) had a life-threatening infectious event of polymicrobial bacterial sepsis reported 2 months after the final chemotherapy administration.

Interpretation: Children with high-risk mature B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab were at risk of prolonged hypogammaglobulinemia, although severe infections were rare. Strategies for immunoglobulin replacement and revaccination are needed.

Funding: Clinical Research Hospital Program of the French Ministry of Health, Cancer Research UK, National Institute for Health Research Clinical Research Network in England, Children's Cancer Foundation Hong Kong, US National Cancer Institute, F Hoffmann-La Roche.

Citing Articles

The Prognostic and Risk Factors for Children With High-Risk Mature B-Cell Non-Hodgkin's Lymphoma: A Retrospective Multicenter Study.

Wang X, Ding L, Fang Y, Yan J, Gao J, Yang L Cancer Med. 2024; 13(21):e70309.

PMID: 39513286 PMC: 11544326. DOI: 10.1002/cam4.70309.


Secondary hypogammaglobulinemia: diagnosis and management of a pediatric condition of clinical importance.

DiGiacomo D, Barmettler S Curr Opin Pediatr. 2024; 36(6):659-667.

PMID: 39254658 PMC: 11560679. DOI: 10.1097/MOP.0000000000001396.


B-NHL Cases in a Tertiary Pediatric Hematology-Oncology Department: A 20-Year Retrospective Cohort Study.

Kyriakidis I, Pelagiadis I, Stratigaki M, Katzilakis N, Stiakaki E Life (Basel). 2024; 14(5).

PMID: 38792653 PMC: 11122206. DOI: 10.3390/life14050633.


Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's....

Sekimizu M, Fukano R, Koga Y, Mitsui T, Fujita N, Mori T BMJ Open. 2024; 14(3):e080762.

PMID: 38508620 PMC: 10953030. DOI: 10.1136/bmjopen-2023-080762.


Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia-a prospective study from CCCG-BNHL-2015.

Dong J, Xu Z, Guo X, Ye F, Fan C, Gao J Heliyon. 2024; 10(5):e27305.

PMID: 38495131 PMC: 10943340. DOI: 10.1016/j.heliyon.2024.e27305.

References
1.
Cheng D, Barton R, Greenway A, Crawford N . Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines. 2016; 15(12):1567-1574. DOI: 10.1080/14760584.2016.1193438. View

2.
Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View

3.
Minard-Colin V, Auperin A, Pillon M, Burke G, Barkauskas D, Wheatley K . Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020; 382(23):2207-2219. PMC: 7720281. DOI: 10.1056/NEJMoa1915315. View

4.
Shearer W, Rosenblatt H, Gelman R, Oyomopito R, Plaeger S, Stiehm E . Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003; 112(5):973-80. DOI: 10.1016/j.jaci.2003.07.003. View

5.
Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S . Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014; 2014:707691. PMC: 4020520. DOI: 10.1155/2014/707691. View